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Introduction: Myocardial infarction followed by heart failure rep-
resents one of the major causes of morbidity and mortality, partic-
ularly in industrialized countries. Engineering and subsequent
transplantation of contractile artificial myocardial tissue and, con-
sequently, the replacement of ischemic and infarcted areas of the
heart provides a potential therapeutic alternative to whole organ
transplantation.
Methods: Artificial myocardial tissue samples were engineered by
seeding neonatal rat cardiomyocytes with a commercially available
3-dimensional collagen matrix. The cellular engraftment within the
artificial myocardial tissues was examined microscopically. Force
development was analyzed in spontaneously beating artificial myo-
cardial tissues, after stretching, and after pharmacologic stimula-
tion. Moreover, electrocardiograms were recorded.
Results: Artificial myocardial tissues showed continuous, rhythmic, and synchro-
nized contractions for up to 13 weeks. Embedded cardiomyocytes were distributed
equally within the 3-dimensional matrix. Application of Ca2 and epinephrine, as
well as electrical stimulation or stretching, resulted in enhanced force development.
Electrocardiographic recording was possible on spontaneously beating artificial
myocardial tissue samples and revealed physiologic patterns.
Conclusions: Using a clinically well-established collagen matrix, contractile myo-
cardial tissue can be engineered in vitro successfully. Mechanical and biologic
properties of artificial myocardial tissue resemble native cardiac tissue. Use of
artificial myocardial tissues might be a promising approach to reconstitute degen-
erated or failing cardiac tissue in many disease states and therefore provide a
reasonable alternative to whole organ transplantation.
Cardiac transplantation represents a life-saving and life-extendingtreatment modality for end-stage heart failure. Although advancesin surgical techniques, immunosuppression, and postoperative carehave improved survival and quality of life, the shortage of donororgans has induced research efforts to develop alternative ap-proaches. One strategy is the in vitro engineering of myocardial
tissue.1-4
Several cardiomyocyte 3-dimensional in vitro culture systems have been devel-
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oped with synthetic polymers or biologic components as the
underlying matrix. Li and associates3 have shown that car-
diac cells can attach to scaffolds to form contractile cell-
polymer constructs. Li and others constructed a viable car-
diac graft that contracted spontaneously in culture
conditions. In most cases cells were derived from fetal rat
ventricular muscle and seeded onto biodegradable material.
Bursac and associates4 have examined the effects of specific
variations in a cell-polymer bioreactor model system, per-
formed electrophysiologic studies, and compared constructs
with native cardiac tissue. Eschenhagen and coworkers5-7
subjected 3-dimensional cultured cardiomyocytes to chronic
stretching to study important features of cardiac diseases,
such as myocardial hypertrophy, which correlates with poor
prognosis in heart failure. This group also performed phar-
macologic studies on engineered heart tissue.
With regard to the potential clinical application, how-
ever, all current models have significant drawbacks or lim-
itations, including size, cellular distribution, viability, and
mechanical stability. Therefore we developed a novel type
of artificial myocardial tissue (AMT). AMT is based on a
clinically approved collagen matrix. Cell isolation and cast-
ing of AMTs have been optimized. The development of
AMTs might be an important step toward a successful,
cell-based restoration of diseased areas of the heart with
poor function.
Materials and Methods
Isolation of Cardiomyocytes
Neonatal Wistar rats (days 1-3) were decapitated according to the
National Institutes of Health and United States Drug Administra-
tion guidelines for the care and use of laboratory animals. Cardi-
omyocytes were isolated essentially as described by Eschenhagen
and coworkers.5 Cardiomyocyte yield and cellular vitality was
assessed microscopically.
Preparation of AMT
Pieces of a preformed collagen scaffold (20 mm  15 mm  2.5
mm, Tissue Fleece, bovine collagen type I, Baxter, Hyland Im-
muno GmbH) were placed in cell-culture dishes and into rectan-
gular wells of the same size that had been cut out of layers
(approximately 5-mm thick) of silicone rubber (Dow Corning).
One milliliter of the cell suspension containing 2  106 cells
was added to the collagen fleece. The mixture was allowed to gel
at 37°C for 4 hours. In a next step 4 mL of culture medium was
added to each well. AMTs were cultured in Minimal Essential
Medium (Life Technologies) plus 10% fetal calf serum (PAA) and
110 mol/L 5-bromo-2-deoxyuridine (Sigma Chemicals). Micro-
scopic examination of cellular distribution and viability, monitor-
ing of contractility, and exchange of culture medium was per-
formed daily.
Histology
AMTs were removed from their silicone wells and fixed in 3%
formaldehyde (Sigma Chemicals) at a pH of 7.4. After dehydra-
tion, AMTs were embedded in paraffin blocks. Longitudinal sec-
tions and cross-sections (10 m) were cut and stained with hema-
toxylin and eosin.
Force Measurements and Electrical Stimulation
AMTs were cut into strips of 10 mm 1.5 mm and were mounted
on a chamber, as described by Kraft and coworkers (Figure 1).8 By
using Histoacryl (Braun), AMT strips (n  10) were glued onto
metal holding arms on both sides of the chamber, which was filled
with culture medium. The temperature inside the chamber was
kept constant at 37°C by using 2 water-cooled Peltier elements.
Figure 1. Force measurement assembly. An AMT strip (thin arrow) is fixed between the force sensor (left side,
arrow) and a mobile holding arm (right side, arrowhead).
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Physiologic oxygen and carbon dioxide levels in the medium were
maintained by means of an external supply. One of the strip
holders was connected to a force transducer (SensoNor). The
opposite holder was flexible to enable stretching of the AMT
strips. AMT-based force generation was recorded digitally and
later used for offline analysis. After baseline measurements, stim-
uli, including Ca (a single dose of 0.25 mmol/mL) and epinephrine
(100 g), were administered to the culture medium. Force gener-
ation was measured. Progressive stretching of each strip at various
lengths was performed in 10-second intervals.
Electrocardiograms to monitor spontaneous electrical activity
of AMTs were performed by using a Grass SD-9 system. Two
separate electrodes were placed inside the AMT and connected to
a standard electrocardiographic monitor. A constant electrode dis-
tance of 5 mm was used in all experiments. Bipolar signals were
recorded.
Results
Shape, Texture, and Stability
Before 3-dimensional seeding, trypan blue staining of
AMTs revealed cellular vitality of 80%  18%. Gelation of
the collagen-cell mixture in culture lasted until day 2. Dur-
ing this process, the cell-seeded and hydrated matrix shrunk,
and the AMTs lost contact with the surrounding silicone
walls and the bottom of the culture dishes. At that point,
they started floating in the culture medium. The definite size
of the AMTs was approximately 15 mm  10 mm  2.5
mm. In this shape they remained stable throughout the entire
culture period of 14 2 weeks without cellular detachment.
After gelation, the AMT texture was flexible and solid,
allowing removal of AMTs from the petri dish without loss
of integrity (Figure 2). AMTs displayed significant elastic-
ity and allowed for stretching of up to 150% of the original
length.
Histology
Hematoxylin and eosin–stained specimens showed a homo-
geneous cell population throughout all layers (center to the
edges), as shown in Figure 3. In addition to single cells, cell
clusters of different sizes were also found within the AMTs.
Contractility
Contractions became apparent 36 hours after casting and
reached maximal frequency and strength on day 4 in 87% of
AMTs. Contractions were synchronous along the total AMT
length. As observed macroscopically and microscopically,
contractions within AMTs were transmitted in wave form.
In culture 40% of AMTs displayed continuous contractility
for 12 weeks. The frequency of contractions was measured
daily and ranged between 40 and 220 beats/min, with an
average frequency of 125  35 beats/min.
Force Measurements
All AMT strips contracted spontaneously and continuously.
Force recordings were performed from 10 different AMTs
before and after stretching. Force development in AMTs
reached 8.6  3.6 N. Stretching resulted in a significant
increase in force (P  .0001). Maximal force was achieved
at 2.5 mm of stretching (25% of initial length of strip),
leading to an increase in force of 119% (18.8  3.7 N)
compared with that seen in unstretched AMTs (Figure 4).
Stretching by more than 3 mm was not possible without
detachment from the holding arm. Stretching, as well as
application of Ca2 or epinephrine, did not affect the rate of
spontaneous contraction. Increase of Ca2 concentrations in
the culture medium from 1.8 to 2.8 mmol/L resulted in a
103% increase in maximal force (14.1  3.9 N, Figure 5).
Figure 2. AMT stability.
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Figure 3. A, Cellular seeding of an AMT: fluorescent stain of AMT after 12 weeks of culture, which demonstrates
intercellular intercalations. B, Electron microscopic study reveals a tight junction between cell and collagen fibril.
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The mean baseline measurement revealed a maximal force
of 6.9  3.4 N. Epinephrine increased the maximal force
from 6.1  0.9 to 10.1  3.4 N (65.6%).
Electrographic Recordings
Electrocardiograms showed amplitudes that ranged between
0.5 and 4.6 mV (mean, 2.1  1.3 mV). The obtained curves
resembled bundle-branch blocks or ectopic ventricular ac-
tivity (Figure 6).
Discussion
Ischemic heart disease and myocardial infarction are major
causes for end-stage heart failure. Currently, heart trans-
plantation is the sole therapeutic option for many of these
patients. Because of the progressive lack of donor organs,
many listed patients die while waiting for a suitable organ.
High-risk coronary surgery, left ventricular restoration with
or without mitral valve surgery, implantation of artificial
assist devices, and biventricular pacemaker implantation are
widely used as treatment concepts in ischemic heart failure.
During the last few years, other strategies have evolved,
aiming at restoring diseased areas of the heart. These ap-
proaches include cellular transplantation, as well as in vitro
engineering of bioartificial myocardial tissue.
Thus far, it is unknown whether cell transplantation
strategies are able to successfully restore severely injured
myocardium. Damaged tissue within infarction areas rap-
idly undergoes irreversible necrosis, leading to structural
alterations, such as scar tissue development. Recent results
of animal studies suggest improvements of heart function
after injection of skeletal myoblasts1 or bone marrow stro-
mal cells.2 However, it is controversial whether these effects
are due to the ability of these cell types to create sufficient
amounts of new myocardium-like tissue within the infarc-
tion area and to participate in synchronized heart contrac-
Figure 4. Stretching of AMTs resulted in increased force devel-
opment, dependent on the length of stretch. We measured force
immediately after stretching AMT strips for 10 seconds (n  10).
Figure 5. Effect of stretch and pharmacologic agents on force
development (left column, baseline; right column, stimulated).
Depicted is the force development in unstimulated AMTs after 10
seconds of stretching (at 2.5 mm), after addition of a further 1
mmol/L Ca2 in culture medium, and after administration of 0.1
mg of epinephrine (n  10 each).
Figure 6. A representative electrocardiographic recording of AMT
is shown. A double-peak signal represents a single complex of
spontaneous electrical activity without stimulation.
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tion. It was criticized that the reported effects are simply
caused by remodeling of connective tissue and extracellular
matrix.
An alternative approach might be the replacement of
diseased myocardium with heart tissue engineered in vitro.
However, all approaches to in vitro–engineered myocardium-
like tissue reported previously3,7 require further improve-
ments to enable clinical use. Potential drawbacks of these
engineered 3-dimensional cultures are as follows: (1) ob-
tained 3-dimensional constructs are too small to allow sur-
gical implantation into infarction areas; (2) cellular distri-
bution and viability are not homogeneous; (3) myocyte
function is limited by various factors, such as impaired
nutrient availability or defective culture geometry; (4)
3-dimensional constructs lack adequate plasticity and me-
chanical stability for implantation purposes; (5) used mate-
rials, especially matrix proteins, are not exactly defined or
clinically approved; and (6) production costs are high be-
cause of expensive additives and collagen compounds, such
as Matrigel.
We have produced a myocardium-like 3-dimensional
tissue, which can be manufactured in various shapes to fit
into infarction scars. Our 3-dimensional culture system is
based on a clinically approved bovine collagen–based ma-
trix, initially designed as a hemostypticum for topical sur-
gical application. By pouring cells into a single-component
scaffold, the seeding procedure can be simplified and short-
ened significantly. During tissue regeneration and remodel-
ing, it is known that autologous cells migrate into the
scaffold. Finally, the natural collagen network disintegrates
after implantation and is replaced with an autologous ma-
trix. Accordingly, migration of myocardial cells into “tissue
fleece” occurred and resulted in artificial myocardium-like
tissue with improved mechanical stability compared with
that of the initial matrix material. Structural integrity of
AMTs was maintained during the entire culture period,
resembling mechanical properties of native cardiac muscle.
In addition to their function as an extracellular scaffold,
matrix proteins supply important migration and prolifera-
tion signals through specific interactions with cellular re-
ceptors. These matrix-cell receptor interactions are essential
to regulate cellular organization within areas of remodeling
tissue. Unfortunately, cell-matrix interactions on the molec-
ular level are widely unknown. Although detailed molecular
mechanisms remain to be analyzed, our results suggest that
collagen fleece provides all signals essential to support the
spreading, attachment, and synchronous contractions of
neonatal cardiomyocytes in the 3-dimensional scaffold. The
observed histologic pattern resembles a compact multilayer
structure.
High densities of contracting cardiomyocytes were de-
tected not only in the peripheral areas of AMTs but also in
the center. Low central-cell density, as observed by others
working on myocardial tissue engineering, has been ex-
plained by oxygen and nutrient deficiency4,6 in the thicker
central areas of the unvascularized 3-dimensional cultures.
Although central areas of AMTs in our studies were about
2.5-mm thick, we did not observe lower cell densities com-
pared with those at the edges of the scaffold. Whether this
is due to a better nutrient supply of collagen fleece com-
pared with that seen with other scaffold mixtures remains
unknown and is subject of ongoing studies at our institution.
For this purpose, we have constructed a novel bioreactor
system with pulsatile flow designed to stimulate angiogen-
esis in 3-dimensional engineered tissues.
One major characteristic of cardiac muscle is the ability
of spontaneous and rhythmic contractions. Macroscopically
visible contractions result from synchronized excitations of
single cardiomyocytes connected through gap junctions.
Spontaneous and synchronous contractions occurred ap-
proximately 36 hours after casting in our AMTs. Maximal
contractions were observed after day 4 and were maintained
for up to 12 weeks of culture. This, to our knowledge,
represents the longest duration of in vitro contractile activity
in the literature. Future experiments will focus on the lon-
gevity of AMTs after in vivo implantation. Comparable
with a heart, contractions spread along the total length of
our engineered myocardium-like tissue in a wave-like man-
ner. Force recordings of native and stretched AMTs re-
vealed stretch-dependent regulation of contractile force,
which is in accordance to the Frank-Starling mechanism.
Furthermore, regulation of contractile force by extrinsic
factors could be measured. Increase of Ca2 and addition of
epinephrine to the culture medium in a physiologic range
lead to enhanced force development. In contrast to the
report of Bursac and associates,4 beating activity in AMTs
was not transient but continuous, even without stimulation
or pacing. The obtained amplitudes were higher than those
previously reported by Bursac and associates, and this might
indicate a more physiologic structure and function of our
engineered heart tissue.
In conclusion, we have engineered a novel and promising
type of myocardium-like tissue that resembles native car-
diac muscle in many aspects. In addition, AMTs might
serve as a basis for the development of tissue, which is
capable of replacing human myocardium in many disease
states of the failing heart. Future progress in stem-cell
technology, as well as discovery of factors responsible for
proliferation of adult cardiomyocytes, combined with suit-
able techniques of gene transfer might allow for the pro-
duction of autologous artificial myocardium-like tissue that
is capable of correcting myocardial injury and restoring
impaired heart function. Finally, vascularization of in vitro–
engineered tissues might result in the generation of a com-
plete bioartificial heart.
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